All podcasts

New Therapies for HERV-Based Disease

Expression from Human Endogenous Retroviruses (HERVs) has been liked to Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS) and other neurological diseases. New therapies may slow or possibly reverse disease progression.

Feb 13, 2022 by Dr. Kevin Folta in Talking Biotech

Apple podcasts link Google podcasts link Spotify podcasts link

Human Endogenous Retroviruses (HERVs) comprise 8% of the human genome and are relics of ancient infections, some dating back to pre-human primates. These resident viral elements can be awakened by viral infections, and have been shown to be tightly associated with diseases like Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS). New data suggest a role for HERVs in the neurological symptoms of long COVID. Today's podcast features a conversation with Jesus Martin-Garcia, CEO and Co-Founder of GeNeuro. New therapies target the rogue proteins arising from these ancient viruses, and show promise in treating, if not reversing, disease progression.

Follow GeNeuro on Twitter

GeNeuro Website

YouTube Videos of their technology


Talking Biotech is brought to you by Colabra – an R&D platform that brings your lab’s world-changing research together in one shared space. Learn more at





The Talking Biotech podcast is distinct from Dr. Kevin Folta's teaching and research roles at the University of Florida. The views expressed on the show are those of Dr. Folta and his guests, and do not reflect the opinions of the university or Colabra.


Get your whole lab on the same page today.

Learn more